Colorectal News and Research

RSS

Physical exercise - one of the most effective methods of preventing disease

Physical exercise is one of the most effective methods of preventing disease. The current issue of Deutsches -rzteblatt International is devoted to this important topic.

24 Nov 2009

Kingston University receives £99,000 for cancer research

Scientists have begun a three-year study to analyse why cancer patients become resistant to treatments designed to fight the disease. A research team from Kingston University has been awarded £99,000 to investigate why some tumours are sensitive and respond to treatments and why other tumours do not.

23 Nov 2009

Recent progress of Delcath Systems in drug delivery platform reported

Delcath Systems, Inc., a medical technology company developing the Delcath Percutaneous Hepatic Perfusion (PHP(TM)) System, a minimally invasive drug delivery platform for the regional treatment of cancer metastatic to the liver, today reported on the Company's recent progress.

19 Nov 2009

Report on unexplained liver haemorrhage after metastasis radiofrequency ablation published

Colorectal carcinoma is one of the most common cancers in the world. Approximately one in four of these patients have metastases at diagnosis, liver being the most common site involved. Although historically it was considered that liver metastases meant a very poor prognosis, today, due to improved systemic therapy, many patients will be candidates for local hepatic treatments such as surgery or less aggressive radiofrequency ablation.

19 Nov 2009

Medspira to manufacture and market Mayo Clinic developed products and technologies

Medspira, and Mayo Clinic have entered into an agreement to commercialize, manufacture and market several Mayo Clinic developed products and technologies invented by Mayo physicians and scientists.

19 Nov 2009

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.

19 Nov 2009

Lee's Pharmaceutical granted exclusive license to Jennerex' lead product for HCC

Jennerex, Inc., a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced in conjunction with Lee's Pharmaceutical Holdings, the execution of a collaboration and license agreement for Jennerex's lead product candidate, JX-594, in certain Asian territories.

18 Nov 2009

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has entered into an agreement with GeneNews (TSX: GEN), of Toronto, Canada, for exclusive rights to market GeneNews’ ColonSentry™, a proprietary blood test for colorectal cancer, in the states of New York and New Jersey.

18 Nov 2009

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.

18 Nov 2009

Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announced

Poniard Pharmaceuticals, Inc. today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC).

18 Nov 2009

Study examines link between folic acid and cancer incidence

Patients with heart disease in Norway, a country with no fortification of foods with folic acid, had an associated increased risk of cancer and death from any cause if they had received treatment with folic acid and vitamin B12, according to a study in the November 18 issue of JAMA.

18 Nov 2009

Press conference highlights emerging treatments in pancreatic cancer

As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET.

18 Nov 2009

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.

17 Nov 2009

Erbitux recognized as one of the major clinical cancer advances of 2009

The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

16 Nov 2009

Researchers identify a molecular mechanism that contributes to colorectal tumors

Researchers at the University of Wisconsin-Madison School of Medicine and Public Health have identified a molecular mechanism that allows two powerful signaling pathways to interact and begin a process leading to colorectal tumors.

16 Nov 2009

Pro-Pharmaceuticals announces financial results for the third quarter and first nine months of fiscal 2009

Pro-Pharmaceuticals, Inc., a developer of galectin-targeted, carbohydrate therapeutic compounds to treat cancer and fibrosis, today reported its financial results for the third quarter and first nine months of fiscal 2009. These results are included in the Company’s Quarterly Report on Form 10-Q for the three- and nine-month periods ended September 30, 2009, which has been filed with the SEC.

13 Nov 2009

CMS approves FDG PET for initial staging of cervical cancer

SNM applauds the Centers for Medicare & Medicaid Services- (CMS) decision to expand coverage of FDG PET for the initial staging of cervical cancer without previously imposed restrictions.

13 Nov 2009

African-Americans more likely to die from colorectal cancer than Caucasians, says new study

New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans.

13 Nov 2009

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented its results on new oral chemotherapy nanoparticle formulation at the AAPS (American Association of Pharmaceutical Scientists) Annual Meeting in Los Angeles (November 8 to 12, 2009).

13 Nov 2009

Tips for preventing cancer

The risk of cancer can be dramatically reduced through everyday choices about diet, exercise and tobacco use, according to a Special Report on Cancer Prevention in the November issue of Mayo Clinic Women's HealthSource.

12 Nov 2009

Colorectal News and Research

Physical exercise - one of the most effective methods of preventing disease

Kingston University receives £99,000 for cancer research

Recent progress of Delcath Systems in drug delivery platform reported

Report on unexplained liver haemorrhage after metastasis radiofrequency ablation published

Medspira to manufacture and market Mayo Clinic developed products and technologies

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Lee's Pharmaceutical granted exclusive license to Jennerex' lead product for HCC

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announced

Study examines link between folic acid and cancer incidence

Press conference highlights emerging treatments in pancreatic cancer

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

Erbitux recognized as one of the major clinical cancer advances of 2009

Researchers identify a molecular mechanism that contributes to colorectal tumors

Pro-Pharmaceuticals announces financial results for the third quarter and first nine months of fiscal 2009

CMS approves FDG PET for initial staging of cervical cancer

African-Americans more likely to die from colorectal cancer than Caucasians, says new study

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

Tips for preventing cancer

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News